114 related articles for article (PubMed ID: 15297045)
1. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
Fernandez-Cruz E; Moreno S; Navarro J; Clotet B; Bouza E; Carbone J; Peña JM; Pérez Molina J; Podzamczer D; Rubio R; Ocaña I; Pulido F; Viciana P; Maradona JA; Blazquez R; Barros C; Quereda C; Rodriguez-Sainz C; Gil J; Abad ML; Díaz L; Cantó C; Muñoz MA; Ferrer E; Jou A; Sirera G; Díaz M; Lopez F; Gatell JM; Gonzalez-Lahoz J;
Vaccine; 2004 Aug; 22(23-24):2966-73. PubMed ID: 15297045
[TBL] [Abstract][Full Text] [Related]
2. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
[TBL] [Abstract][Full Text] [Related]
4. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
Valor L; Navarro J; Carbone J; Rodríguez-Sáinz C; Gil J; López F; Fernández-Cruz E;
Vaccine; 2008 May; 26(22):2738-45. PubMed ID: 18433946
[TBL] [Abstract][Full Text] [Related]
5. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
Chantratita W; Sukeepaisarncharoen W; Chandeying V; Kulpradist S; Israngkura Na Ayudhtaya B; Rugpao S; Sirawaraporn W; Boonshuyar C; Churdboonchart V
HIV Med; 2004 Sep; 5(5):317-25. PubMed ID: 15369506
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
Moss RB; Li L; Giermakowska WK; Lanza P; Turner JL; Wallace MR; Jensen FC; Richieri SP; Daigle AE; Theofan G; Carlo DJ
J Hum Virol; 1998; 1(2):77-81. PubMed ID: 10195235
[TBL] [Abstract][Full Text] [Related]
7. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.
Patterson BK; Carlo DJ; Kaplan MH; Marecki M; Pawha S; Moss RB
AIDS; 1999 Sep; 13(13):1607-11. PubMed ID: 10509560
[TBL] [Abstract][Full Text] [Related]
8. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
[No Abstract] [Full Text] [Related]
9. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
[TBL] [Abstract][Full Text] [Related]
11. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
García F; Lejeune M; Climent N; Gil C; Alcamí J; Morente V; Alós L; Ruiz A; Setoain J; Fumero E; Castro P; López A; Cruceta A; Piera C; Florence E; Pereira A; Libois A; González N; Guilá M; Caballero M; Lomeña F; Joseph J; Miró JM; Pumarola T; Plana M; Gatell JM; Gallart T
J Infect Dis; 2005 May; 191(10):1680-5. PubMed ID: 15838795
[TBL] [Abstract][Full Text] [Related]
13. New strategies to combat HIV: augmenting antiviral immunity.
Smith KA; Boyle BA
AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321
[No Abstract] [Full Text] [Related]
14. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
[TBL] [Abstract][Full Text] [Related]
15. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
17. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.
Trabattoni D; Clivio A; Bray DH; Bhagat L; Beltrami S; Maffeis G; Cesana E; Lowry P; Lissoni F; Kandimalla ER; Sullivan T; Agrawal S; Bartholomew R; Clerici M
Vaccine; 2006 Feb; 24(9):1470-7. PubMed ID: 16221513
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
[TBL] [Abstract][Full Text] [Related]
19. The preventive phase I trial with the HIV-1 Tat-based vaccine.
Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Tripiciano A; Longo O; Bellino S; Francavilla V; Paniccia G; Arancio A; Scoglio A; Collacchi B; Ruiz Alvarez MJ; Tambussi G; Tassan Din C; Palamara G; Latini A; Antinori A; D'Offizi G; Giuliani M; Giulianelli M; Carta M; Monini P; Magnani M; Garaci E
Vaccine; 2009 Dec; 28(2):371-8. PubMed ID: 19879233
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
